WPA launches insurance for cancer drugs

WPA has launched an insurance product that provides access to cancer-treating drugs.

Mycancerdrugs provides up to £50,000 lifetime benefit for advanced cancer drugs that have been licensed by the European Medicines Agency (EMEA). Where the NHS declines to administer the drug, Mycancerdrugs will fund all the costs directly associated with administering the drug privately up to the £50,000 lifetime benefit.

Applicants will not be eligible for cover where they have had or currently have cancer; are on a medically supervised health screening or review programme because they are considered to be at a higher risk of developing cancer, or have a parent or sibling who developed or died from cancer before the age of 60 years.

The insurance is intended to improve the availability of cancer drugs that are not available to patients on the NHS in England or Wales. Despite being licensed for use by the EMEA and available in Scotland, some drugs are awaiting approval by the National Institute for Health and Clinical Excellence, while others are waiting for local health authority funding.